Last reviewed · How we verify
glypressin
glypressin is a Small molecule drug developed by Tanta University. It is currently in Phase 1 development for Hepatorenal syndrome. Also known as: vasopressin.
Glypressin is a vasoactive drug that binds to the vasopressin V1 receptor, classified as a binding agent. It is used in the management of conditions such as bleeding gastric varices, hepatorenal syndrome, acute kidney injury, septic shock, and sepsis.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Anti-infectives pathway favourability
+2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | glypressin |
|---|---|
| Also known as | vasopressin |
| Sponsor | Tanta University |
| Target | Vasopressin V1a receptor, Vasopressin V2 receptor |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 1 |
Approved indications
- Hepatorenal syndrome
Common side effects
Key clinical trials
- Double Plasma Separation and Adsorption in Acute-on-Chronic Liver Failure (DPMAS-ACLF Trial) (NA)
- Comparison of Terlipressin Versus Octreotide in Patients With Hepatorenal Syndrome (NA)
- Interest of in Situ Terlipressin Administration Before the Realisation of Bronchial Biopsy (PHASE3)
- Effects of Terlipressin and Somatostatin on Portal Pressure in Patients Undergoing Living Donor Liver Transplantation (NA)
- Terlipressin in Combined Hepatorenal Syndrome in Patients With Signs of Chronic Renal Disease
- Terlipressin vs. Somatostatin in Cirrhotic Patients With Acute Gastrointestinal Bleeding and Acute Kidney Injury (NA)
- Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics (PHASE1)
- Gut-Liver Axis Modulation With IgG-Enriched Immunotherapy in Severe Alcohol-Associated Hepatitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- glypressin CI brief — competitive landscape report
- glypressin updates RSS · CI watch RSS
- Tanta University portfolio CI
Frequently asked questions about glypressin
What is glypressin?
What is glypressin used for?
Who makes glypressin?
Is glypressin also known as anything else?
What development phase is glypressin in?
What does glypressin target?
Related
- Target: All drugs targeting Vasopressin V1a receptor, Vasopressin V2 receptor
- Manufacturer: Tanta University — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Hepatorenal syndrome
- Also known as: vasopressin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing